SPOTLIGHT -
Anthracyclines and Trastuzumab Bests Taxane/Carboplatin/Trastuzumab
Anthracycline chemotherapy plus trastuzumab outperformed anthracycline alone, and performed similarly to a non-anthracycline regimen in breast cancer patients.
Read More
Update Shows Adding Bevacizumab to Chemotherapy Improves Survival
Updated results confirm that addition of bevacizumab to docetaxel as first-line breast cancer treatment improves survival and response rates.
Sorafenib Works Well With Chemotherapy in Advanced Breast Cancer
Sorafenib showed promise when combined with chemotherapy for locally advanced or metastatic breast cancer.
Adding Bevacizumab to Chemotherapy Prolongs Survival in Breast Cancer
Adding bevacizumab to chemotherapy improved survival compared with chemotherapy alone in breast cancer patients.
Alcohol and Obesity Raise Risk of Breast Cancer Recurrence
Consumption of just a half drink per day, or two to three per week, raised the risk of recurrence of breast cancer in women by 39%.
Exemestane Is Superior to Tamoxifen in Postmenopausal Breast Cancer
Postmenopausal women with breast cancer who use exemestane after taking tamoxifen have superior outcomes than those who stay on tamoxifen for 5 years.
Tamoxifen/AI Sequencing as Effective as Continuous 5-Year AI Therapy
Which is better: Tamoxifen upfront followed by an aromatase inhibitor (AI) for 5 years, or an AI for 5 years. Final results failed to resolve this issue.
Do Bisphosphonates Protect Against Breast Cancer?
The use of oral bisphosphonates may protect against the development of invasive breast cancer, according to a new analysis by the Women's Health Initiative.
